The Greenwich Biosciences mission is rooted in unlocking the potential of cannabinoid medicines to address serious medical conditions with limited treatment options.
The world has only recently started to recognize the true potential of cannabinoids to help people with challenging conditions. But we have been advancing the science for more than 2 decades. Much of what is known about cannabinoids was discovered by our researchers. And there’s still so much more to learn.
We created the first-ever controlled clinical trial program evaluating a cannabinoid medicine, for patients with Dravet syndrome and Lennox-Gastaut syndrome (LGS). Our products are backed by science, independently vetted, FDA-approved, and consistently manufactured—because we believe no cannabinoid should go to market without the data evaluating its safety profile, efficacy, and its potential to help.
There is so much potential for cannabinoid medications to transform the lives of patients living with a range of serious illnesses. Together with our parent company, GW Pharmaceuticals plc, we have a robust pipeline for clinical development, pioneering significant advancements in the development of cannabinoid-derived therapies for patients living with a range of serious illnesses, such as epilepsy, glioblastoma, schizophrenia, and autism spectrum disorders. Our success to date gives us hope for the future.
Everyone who works at Greenwich Biosciences is united in one shared belief: that cannabinoids have the incredible potential to transform the lives of patients and families.
We never forget who we’re striving for
We are here to change lives
We challenge ourselves to find new and better approaches
We accomplish more through working together and valuing one another
We take responsibility and deliver on our commitments
We are fair, honest, and ethical
We pursue the highest standards for ourselves and for our industry